MLEC

+ Watchlist + Portfolio

Moolec Science SA

Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.81
52-Week Range: $3.08 – $23.22
Market Cap: $3.45M
P/E (TTM): —
EPS (TTM): -199.02
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.80
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: —
Debt/Equity: —
Total Debt: —
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: —

MLEC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$420.87M	$466.38M	$333.61M
Cost of Revenue	$0.00	$241.65M	$287.06M	$207.87M
Gross Profit	$0.00	$179.22M	$179.31M	$125.74M
Research & Development	$985.16K	$15.94M	$17.42M	$15.14M
Selling, General & Admin	$2.63M	$88.61M	$93.99M	$88.83M
Operating Expenses	$3.65M	$128.61M	$137.55M	$129.25M
Operating Income	-$3.65M	$50.61M	$41.76M	-$3.51M
EBITDA	-$4.52M	$100.87M	$29.16M	-$109.67M
Pretax Income	-$4.53M	$50.79M	-$27.96M	-$170.00M
Income Tax	$0.00	-$2.33M	$1.10M	$6.64M
Net Income	-$4.53M	$40.44M	-$32.69M	-$111.46M
Diluted EPS	-18.08	132.05	-28.50	-258.69
Diluted Shares	250401	306214	256568	430864

MLEC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.08M	$2.53M	$52.99M	$767.92K
Receivables	$0.00	$1.69M	$237.08M	$19.93M
Inventory	$0.00	$465.75K	$126.22M	$2.24M
Current Assets	$1.08M	$5.33M	$438.21M	$31.19M
Total Assets	$5.69M	$24.05M	$949.84M	$204.71M
Current Liabilities	$4.09M	$12.60M	$427.40M	$236.05M
Long-Term Debt	—	$99.05K	$208.06M	$19.61M
Total Debt	—	$2.65M	$453.85M	$246.88M
Total Liabilities	$4.09M	$13.95M	$699.84M	$287.58M
Retained Earnings	-$6.83M	-$58.62M	$1.14M	-$110.32M
Shareholders' Equity	$1.60M	$10.11M	$1.21M	-$65.97M
Working Capital	-$3.00M	-$7.27M	$10.80M	-$204.86M
Net Debt	—	$117.62K	$389.57M	$245.99M

MLEC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.89M	-$41.16M	$39.56M	$3.64M
Capital Expenditure	—	-$22.93M	-$25.03M	-$14.62M
Free Cash Flow	-$1.89M	-$64.09M	$14.53M	-$10.98M
Depreciation & Amortisation	$1.70K	$19.51M	$21.33M	$22.25M
Stock-Based Compensation	$838.58K	$3.48M	$14.20M	$4.39M
Investing Cash Flow	$0.00	-$25.59M	-$27.40M	-$35.99M
Financing Cash Flow	$2.00M	$76.22M	-$1.49M	-$15.02M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Share Repurchases	—	-$3.00M	-$734.39K	-$926.90K
Net Change in Cash	$114.02K	$9.47M	$10.66M	-$47.37M

MLEC Income statement, quarterly periods, in USD
USD	Q4 2024	Q4 2025
Revenue	$2.64M	—
Cost of Revenue	$3.32M	—
Gross Profit	-$674.37K	—
Research & Development	$298.00K	—
Selling, General & Admin	$899.55K	—
Operating Expenses	$1.39M	—
Operating Income	-$2.06M	—
EBITDA	-$1.33M	—
Pretax Income	-$2.15M	—
Income Tax	$280.89K	—
Net Income	-$2.43M	—
Diluted EPS	-9.00	—
Diluted Shares	259739	—

MLEC Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q4 2025
Cash & Equivalents	—	$1.04M
Receivables	—	$3.97M
Inventory	—	$3.99M
Current Assets	—	$9.19M
Total Assets	—	$103.39M
Current Liabilities	—	$61.88M
Long-Term Debt	—	$12.03M
Total Debt	—	$66.48M
Total Liabilities	—	$88.21M
Retained Earnings	—	-$44.57M
Shareholders' Equity	—	$9.22M
Working Capital	—	-$52.69M
Net Debt	—	$65.36M

MLEC Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q4 2025
Operating Cash Flow	-$2.15M	—
Capital Expenditure	-$298.86K	—
Free Cash Flow	-$2.09M	—
Depreciation & Amortisation	-$324.61K	—
Stock-Based Compensation	-$285.56K	—
Investing Cash Flow	-$9.93M	—
Financing Cash Flow	-$8.32M	—
Dividends Paid	$0.00	—
Net Change in Cash	-$20.40M	—

Market Snapshot

About

Moolec Science SA is a molecular farming company that uses plants to produce animal proteins and other high-value ingredients. The company leverages biotechnology to grow proteins in soybeans and other crops, aiming to create sustainable alternatives to traditional animal agriculture. Moolec focuses on developing ingredients for the food and pharmaceutical industries.